Inactivated rabies vaccine control and release: Use of an ELISA method

Biologicals

Volumn 31, Issue 1, 2003, Pages 9-16

  Fournier Caruana, Jacqueline ^a   Poirier, Bertrand ^a   Haond, Geneviève ^a   Jallet, Corinne ^b   Fuchs, Florence ^a   Tordo, Noël ^b   Perrin, Pierre ^b  

^a AFSSAPS   (France)

^b INSTITUT PASTEUR   (France)

Author keywords

Batch release; ELISA method; Glycoprotein; Rabies vaccine; Statistics

Indexed keywords

DIPLOID CELL VACCINE; INACTIVATED VACCINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS GLYCOPROTEIN;

ANALYTIC METHOD; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; INTERMETHOD COMPARISON; OPTICAL DENSITY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN CONTENT; QUALITY CONTROL; VACCINE PRODUCTION; VALIDATION PROCESS; VERO CELL;

RABIES VIRUS;

EID: 0037338007     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1045-1056(02)00070-2     Document Type: Article

References (27)

1. Official control Authority Batch Release of Rabies Vaccine. PA/PH/OMCL (96) 16, DEF.
2. Rabies inactivated vaccine for human use. Eur Ph 1997, corrected 2000;0216:1329-1331.
3. WHO Requirements for rabies vaccine. WHO Tech Rep Ser. 658:1981;57-85.
4. WHO Requirements for rabies vaccine. WHO Tech Rep Ser. 760:1987;180-209.
5. Eighth Report. WHO Tech Rep Ser. 824:1992;1-90.
6. WHO Requirements for rabies vaccine. WHO Tech Rep Ser. 840:1994;202-207.
7. Seligmann E.B. Jr. The NIH test for potency. Kaplan M.M., Koprowski H. Laboratory Techniques in Rabies. 3rd ed. 1973;279-286 WHO.
8. Wiktor T., Gyorgy E., Schlumberger D., Sokol F., Koprowski H. Antigenic properties of rabies virus components. J Immunol. 110:1973;269-276.
9. Perrin P., Thibodeau L., Sureau P. Rabies immunosome (subunit vaccine) structure and immunogenicity. Pre- and post exposure protection studies. Vaccine. 3:1985;325-332.
10. Ferguson M., Schild G.C. A single radial immuno-diffusion technique for the assay of rabies glycoprotein antigen: application for potency tests of vaccines against rabies. J Gen Virol. 59:1982;197-201.
11. Ferguson M., Seagroatt V., Schild G.C. A collaborative study on the use of single radial immuno-diffusion for the assay of rabies virus glycoprotein. J Biol Stand. 13:1985;295-301.
12. Perrin P., Lafon M., Sureau P. Enzyme linked immuno-sorbent assay (ELISA) for the determination of glycoprotein content of rabies vaccines. Meslin F.-X., Kaplan M.-M., Koprowski H. Laboratory Techniques in Rabies. 4th ed. 1996;383-388 WHO, Geneva.
13. Lyng J., Bentzon M.W., Ferguson M., Fitzgerald E.A. Rabies vaccine standardization: International collaborative study for the characterization of the fifth International standard for rabies vaccine. Biologicals. 20:1992;301-313.
14. Lafon M. Technique for the production, sceening and characterization of monoclonal antibodies. Meslin F.-X., Kaplan M.-M., Koprowski H. Laboratory Techniques in Rabies. 4th ed. 1996;133-144 WHO, Geneva.
15. Jallet C., Jacob Y., Bahloul C., Drings A., Desmézières E., Tordo N., Perrin P. Chimeric lyssavirus glycoproteins with increased immunological potential. J Virol. 73:1999;225-233.
16. Schild G.C., Wood J.M., Newman R.W. A single radial immuno-diffusion technique for the assay of influenza haemagglutinin antigen. Bull of WHO. 52:1975;230-233.
17. Wood J.M., Schild G.C., Newman R.W., Seagroatt V. An improved single radial immuno-diffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J Biol Stand. 5:1977;237-247.
18. Béranger G., Gibelin N., Largaigt G. Modèle mathématique pour le calcul de l'activité des vaccins antigrip-paux par la méthode d'immunodiffusion radiale. Sci Techn Pharm. 2:1981;83-92.
19. European Pharmacopoeia. Chapter 5.3, Statistical analysis of results of biological assays and tests.
20. AFNOR-NF X 06-031-1, Application de la statistique, Cartes de contrôle, Partie 1: Cartes de de contrôle de Shewhart aux mesures.
21. Rooijakkers E.J.M., Uittenbogaard J.P., Groen J. Osterhaus ADME. Rabies vaccine potency control: comparison of ELISA systems for antigenicity testing. J Virol Meth. 58:1996;111-119.
22. Ferguson M., Heath A. Report of a collaborative study to assess the determination of glycoprotein antigen content of rabies vaccines for human use. Biologicals. 20:1992;143-154.
23. Gamoh K., Senda M., Itoh O., Muramatsu M., Hirayama, Koike R., Endoh Y.S., Minamoto N. Use of ELISA for in vitro potency test of rabies vaccines for animal use. Biologicals. 24:1996;96-101.
24. Rooijakkers E.J.M., Groen J., Uittenbogaard J.P., Van Herwijnen J. Osterhaus ADME. Development and evaluation of alternative testing methods for the in vivo NIH potency test used for the quality control of inactivated rabies vaccine. Dev Biol Stand Basel, Karger. 86:1996;137-145.
25. Wunner W., Dietzschold B., Curtis P., Wiktor T. Rabies subunits vaccines. J Gen Virol. 64:1983;1649-1656.
26. Lafon M., Perrin P., Versmisse P., Sureau P. Use of monoclonal antibody for quantitation of rabies vaccine glycoprotein by immunoassay. J Biol Standard. 13:1985;295-301.
27. Gaudin Y., Tuffereau C., Durrer P., Flamand A., Ruigrok R. Biological function of the low-pH, fusion-inactive conformation of rabies virus glycoprotein (G): G is transported in a fusion-inactive state-like conformation. J Virol. 69:1995;5528-5534.